Ana Drozdowskyj

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Niki Karachaliou, María González‐Cao, Guillermo Crespo et al. · Therapeutic Advances in Medical Oncology · 2018 · 274 citations · Full text

Medicine, Immunology, Oncology +17

Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt et al. · JAMA Oncology · 2015 · 238 citations · Full text

Medicine, Molecular Biology, Oncology +17

The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i> -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

Carlota Costa, Miguel Angel Molina, Ana Drozdowskyj et al. · Clinical Cancer Research · 2014 · 228 citations · Full text

Medicine, Oncology, Pharmacology +15

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

Imane Chaib, Niki Karachaliou, Sara Pilotto et al. · JNCI Journal of the National Cancer Institute · 2017 · 216 citations · Full text

Medicine, Oncology, Pharmacology +17